Home  »  Business   »  Analyst Forecast For Arbutus Biopharma Corporation...

Analyst Forecast For Arbutus Biopharma Corporation (NASDAQ: ABUS)

The trading price of Arbutus Biopharma Corporation (NASDAQ:ABUS) closed higher on Tuesday, June 21, closing at $2.72, 1.49% higher than its previous close.

Traders who pay close attention to intraday price movement should know that it fluctuated between $2.68 and $2.86. In examining the 52-week price action we see that the stock hit a 52-week high of $6.50 and a 52-week low of $1.93. Over the past month, the stock has gained 16.24% in value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Arbutus Biopharma Corporation, whose market valuation is $387.90 million at the time of this writing, is expected to release its quarterly earnings report Nov 01, 2021 – Nov 05, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.13 per share this quarter, however they have predicted annual earnings per share of -$0.52 for 2022 and -$0.62 for 2023. It means analysts are expecting annual earnings per share growth of 37.30% this year and -19.20% next year.

Analysts have forecast the company to bring in revenue of $6.77 million for the current quarter, with the likely lows of $3.21 million and highs of $10.3 million. The average estimate suggests sales will likely up by 190.70% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2022 is $32.07 million. The company’s revenue is forecast to grow by 191.90% over what it did in 2022.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Arbutus Biopharma Corporation No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest ABUS has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.

A quick review shows that ABUS’s price is currently 8.76% off the SMA20 and 9.29% off the SMA50. The RSI metric on the 14-day chart is currently showing 58.44, and weekly volatility stands at 7.59%. When measured over the past 30 days, the indicator reaches 7.44%. Arbutus Biopharma Corporation (NASDAQ:ABUS)’s beta value is currently sitting at 2.37, while the Average True Range indicator is currently displaying 0.19. With analysts defining $4.00-$10.00 as the low and high price targets, we arrive at a consensus price target of $6.70 for the trailing 12-month period. The current price is about -47.06% off the estimated low and -267.65% off the forecast high, based on this estimate. Investors will be thrilled if ABUS’s share price rises to $6.00, which is the median consensus price. At that level, ABUS’s share price would be -120.59% below current price.

To see how Arbutus Biopharma Corporation stock has been performing in comparison to its peers in the industry, here are the numbers: ABUS stock’s performance was 1.49% in the latest trading, and -13.65% in the past year, while Infinity Pharmaceuticals Inc. (INFI) has traded -4.40% on the day and positioned -79.06% lower than it was a year ago. Also in last trading session, the S&P 500 Index has surged 2.45%, while the Dow Jones Industrial also saw a positive session, up 2.15% on the day.

An evaluation of the daily trading volume of Arbutus Biopharma Corporation (NASDAQ:ABUS) indicates that the 3-month average is 1.28 million.

Currently, records show that 148.43 million of the company’s shares remain outstanding. The insiders hold 27.11% of outstanding shares, whereas institutions hold 29.80%. However, since the stock’s price has seen -30.08% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts